Minimally invasive glaucoma surgery, or MIGS, is one of the most promising new developments in glaucoma treatment. MIGS is a term applied to a range of gentle procedures developed to lower eye pressure in patients with open-angle glaucoma using microscopic equipment and tiny incisions. While there is no cure for glaucoma, MIGS can greatly decrease glaucoma medications, slow disease progression, and delay the surgical need.
Dr. Sarkisian specializes in a full range of MIGS procedures and may recommend one or a combination of these to treat your unique condition:
- XEN Gel Stent
- OMNI procedure
- Ab-Interno Canaloplasty
- iStent inject
- Endoscopic CycloPhotocoagulation (ECP)
- Kahook Dual-Blade Treatment
Enroll in FDA Clinical Trials for MIGS
Dr. Sarkisian has served as a lead- and co-investigator for numerous glaucoma technology studies to determine FDA approval. He is currently highly involved and actively enrolling patients in FDA clinical trials for MIGS procedures, such as iStent Supra, STARflo, and iDose, as well as for conventional glaucoma treatment options, such as glaucoma drainage, implants, and filtering procedures.
Ready to take control of your glaucoma and achieve more freedom from glaucoma medication? Request an appointment at Oklahoma Eye Surgeons to find out if you may be a good candidate for a MIGS clinical trial.